Evidence map›Paper›PMID 33313847›Full record

ArticleOperative neurosurgery (Hagerstown, Md.)2020

Thrombolysis for Evacuation of Intracerebral and Intraventricular Hemorrhage: A Guide to Surgical Protocols With Practical Lessons Learned From the MISTIE and CLEAR Trials.

Sean P Polster, Julián Carrión-Penagos, Seán B Lyne, Fernando D Goldenberg, Ali Mansour, Wendy Ziai, Andrew P Carlson, Paul J Camarata, Jean-Louis Caron, Mark R Harrigan and 6 more

Open access · greenAbstract read
In one paragraph

Article in Operative neurosurgery (Hagerstown, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Post-Trial Enhanced Deployment and Technical Performance with the MISTIE Procedure per Lessons Learned.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2021
    Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 2 countries.

Sean P PolsterNeurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
Julián Carrión-PenagosNeurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
Seán B LyneNeurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
Fernando D GoldenbergNeurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
Ali MansourNeurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
Wendy ZiaiDivision of Brain Injury Outcomes, Department of Neurology, Johns Hopkins University Medical Institutions, Baltimore, Maryland.
Andrew P CarlsonDepartment of Neurosurgery, University of New Mexico School of Medicine, Albuquerque, New Mexico.
Paul J CamarataDepartment of Neurosurgery, University of Kansas School of Medicine, Kansas City, Kansas.
Jean-Louis CaronDepartment of Neurosurgery, University of Texas, San Antonio, Texas.
Mark R HarriganDivision of Neurosurgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
Barbara GregsonNeurosurgical Trials Group, Newcastle University, Newcastle upon Tyne, United Kingdom.
A David MendelowNeurosurgical Trials Group, Newcastle University, Newcastle upon Tyne, United Kingdom.
Mario ZuccarelloDepartment of Neurosurgery, University of Cincinnati Medical Center, Cincinnati, Ohio.
Daniel F HanleyDivision of Brain Injury Outcomes, Department of Neurology, Johns Hopkins University Medical Institutions, Baltimore, Maryland.
Robert DoddDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, California.
Issam A AwadNeurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, Illinois.
University of Chicago · USJohns Hopkins University · USNewcastle University · GBStanford University · USThe University of Texas at San Antonio · USUniversity of Alabama at Birmingham · USUniversity of Cincinnati · USUniversity of Kansas · USUniversity of New Mexico · US

Funding

MISTIE III_ Lead Grant_ Cluster Application for the Clinical Coordinating CenterU01NS080824 · NINDS · JOHNS HOPKINS UNIVERSITY · PI HANLEY, DANIEL F · 2013 to 2017
$23.2M
Clot Lysis: Evaluating Accelerated Resolution of IVH Phase III (CLEAR III)U01NS062851 · NINDS · JOHNS HOPKINS UNIVERSITY · PI HANLEY, DANIEL F · 2009 to 2013
$21.6M
NINDS NIH HHS U01 NS062851NINDS NIH HHS U01 NS080824
6 · The paper itself

Abstract

backgroundMinimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) procedure was recently tested in a large phase III randomized trial showing a significant probability of functional benefit in those cases that reached the goal hematoma evacuation of ≤15 mL residual (or ≥70% removal). Benefit of thrombolysis was also identified in cases with large intraventricular hemorrhage, and achieving at least 85% volume reduction in the Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR) III trial.

objectiveTo protocolize steps in the MISTIE and CLEAR procedures in order to maximize hematoma evacuation and minimize complications.

methodsWe articulate data-driven lessons and expert opinions surrounding the factors of patient selection, catheter placement, and dosing, which impacted safety and surgical performance in the MISTIE and CLEAR trials.

resultsModifiable factors to maximize evacuation efficiency include optimizing catheter placement and pursuing aggressive dosing to achieve treatment goals, while strictly adhering to the safety steps as articulated in the respective trials. Prognostic factors that are viewed as nonmodifiable include greater initial intracerebral hemorrhage volume with irregular shape, smaller intraventricular bleeds, and the uncommon but consequential development of new bleeding during the dosing period despite strict protocol adherence.

conclusionsSurgeon education in this tutorial is aimed at maximizing the benefit of the MISTIE and CLEAR procedures by reviewing case selection, safety steps, treatment objectives, and technical nuances. Key lessons include stability imaging, etiology screening, and technical adherence to the protocol in order to achieve defined thresholds of evacuation.

Indexed as

Fibrinolytic AgentsTissue Plasminogen ActivatorCerebral HemorrhageHumansMinimally Invasive Surgical ProceduresThrombolytic TherapyFibrinolytic AgentsTissue Plasminogen ActivatorCLEARIntracerebral hemorrhage (ICH)Intraventricular hemorrhage (IVH)Minimally invasive surgeryMISTIESurgical performanceThrombolysis

Identifiers

PMID33313847
PMCPMC7891242
OpenAlexW3113258533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.